Noradrenalin Laboratoire Aguettant (Noradrenaline Tartrate)

Noradrenaline tartrate acts as a direct agonist at alpha‑1 adrenergic receptors on vascular smooth muscle, causing powerful vasoconstriction. This increases systemic vascular resistance and arterial pressure. It also stimulates beta‑1 receptors modestly, which can enhance cardiac contractility, together providing rapid pressor support.

The dosing regimen for Noradrenalin Laboratoire Aguettant is individualized and must be determined by the treating physician. Dosage is typically expressed as a continuous intravenous infusion, titrated to achieve the desired blood pressure target while monitoring the patient’s response and side‑effects.

Safety data for noradrenaline in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be administered under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Noradrenalin is generally preferred over dopamine or phenylephrine for most forms of septic shock because it provides reliable arterial pressure elevation with fewer tachyarrhythmic effects. Unlike phenylephrine, it also offers modest beta‑1 activity, supporting cardiac output, while dopamine may cause more dose‑dependent side effects.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Before use, inspect the vial for particulate matter and ensure the solution is at room temperature if required for administration, following aseptic technique.

Noradrenalin is given as a continuous intravenous infusion, usually via a central venous catheter. The infusion is prepared in a compatible diluent, and the rate is titrated based on real‑time blood pressure measurements and patient response, with frequent hemodynamic monitoring.

The most critical risks include severe hypertension, cardiac arrhythmias such as ventricular tachycardia, and peripheral tissue ischemia that can progress to necrosis if extravasation occurs. Prompt recognition and dose adjustment are essential to mitigate these potentially life‑threatening complications.

Contraindications include patients with pre‑existing severe hypertension, uncorrected hypovolemia, or peripheral vascular disease that predisposes to ischemia. Caution is also advised in individuals with recent myocardial infarction, uncontrolled tachyarrhythmias, or those receiving MAO inhibitors.